Psyched Wellness Receives DTC EligibilityCybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug ApplicaRritual Appoints Sarton Molnar-Fenton, Vice President Sales USATryp Therapeutics Announces Listing on OTCQB and DTC EligibilityPure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay OffTryp Therapeutics Appoints Greg McKee as Chief Executive OfficerPsyence Group and Pure Extracts Sign JV Letter of Intent for the Extraction of Psilocybin from Psychedelic Mushrooms andCybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United StatesPsyched Wellness Initiates Study on AME-1 Extract for Gut HealthRritual Superfoods to Launch Product Line in Rite Aid Stores – NationwideMushroomStocks.com Deep Dive: Tryp Therapeutics (CSE:TRYP)Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (Field Trip Has A Warchest Of Cash To Propel R&D and M&A Moving ForwardCybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The HorizonPure Extracts Orders Cutting Edge Vitalis Cosolvent Injection SystemTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of PsychedelicsCybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th PrRritual Announces Successful Completion of Second Full Scale Manufacturing Run and Commencement of Third Full Scale ManuNuminus Wellness Is Taking Strides To Advance Its R&D Business UnitRritual Announces Successful Launch of US Facing E-Commerce Website and Provides Corporate Update
Back

Cybin Inc. Is Rapidly Progressing Its Drug Development Program With Plenty On The Horizon

Mar 18, 2021 • 10:09 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Earlier this year, Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) completed a go-public transaction on the NEO Exchange and has captured our attention. The biotechnology company is focused on advancing psychedelic therapeutics through clinical trials and we are favorable on how the story has advanced so far this year.

Yesterday, Cybin announced an important milestone and reported to have completed its 20th pre-clinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (IND)-enabling studies.

When we first started to cover Cybin, we were excited about the opportunity due to the strength of the management team, the focus on creating a leading intellectual property (IP) portfolio, and the structure of the business.

As it relates to Cybin progressing CYB003 and CYB004, we believe the company benefited from having strategic relationships with a variety of companies that specialize in certain areas. For these proprietary psychedelic molecules, Cybin has completed key research studies both in vitro and in vivo. These studies were based on Cybin’s proprietary state-of-the-art technologies and we are favorable on how the business is positioned for growth.

CYB003 and CYB004 have entered into full IND-enabling studies in preparation for defined clinical testing in serious psychiatric conditions that have large unmet medical needs. Cybin also reported to have initiated an active pharmaceutical ingredient (API) manufacturing contract with a strategic pharmaceutical manufacturing partner and we are favorable on this.

Cybin has developed a discovery pipeline of over 50 proprietary psychedelic molecules, multiple proprietary delivery mechanisms, and supportive technology platforms, all protected under its ever-growing IP portfolio. Going forward, the company will continue to progress its novel next-generation psychedelics that have improved bioavailability and optimized pharmacokinetic profiles that could result in reduced side effects.

So far this year, Cybin has reported several significant developments as it relates to its IP portfolio, current studies, and balance sheet. The market seems to have become more favorable on Cybin and this is a trend that we will closely following on a going forward basis.

If you are interested in learning more about Cybin’s recent developments., please send an email to support@technical420.com with the subject “Cybin Corp” to be added to our distribution list.

 

 

 

 

This news release contains forward-looking statements relating to the future operations of Cybin Corp, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Cybin Corp’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Cybin Corp. include risks detailed from time to time in the filings made by Cybin Corp. under securities regulations.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link